Keyphrases
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
100%
Overall Survival
42%
Multiple Myeloma
38%
Melanoma
35%
Multiple Myeloma Patients
32%
Newly Diagnosed multiple Myeloma
25%
Selinexor
25%
Autologous Transplantation
24%
Progression-free Survival
22%
Single Center
22%
Advanced Solid Tumors
18%
Neoadjuvant
18%
Graft-versus-host Disease (GvHD)
17%
Multi-arm
16%
High-risk Myeloma
16%
Hazard Ratio
16%
Phase Ib Study
15%
Nivolumab
15%
High Risk
15%
Confidence Interval
14%
Lenalidomide
14%
Immune Checkpoint Blockade
13%
Metastatic Melanoma
13%
Multivariable
11%
Ipilimumab
11%
Survival Outcomes
11%
High-risk Cytogenetics
11%
Minimal Residual Disease
10%
Melanoma Patients
10%
Carboplatin
10%
Lymphoid Malignancies
9%
Paclitaxel
9%
Median Progression-free Survival
9%
Busulfan
9%
MD Anderson Cancer Center
9%
Response Evaluation Criteria in Solid Tumors (RECIST)
9%
Acral Lentiginous Melanoma
9%
Metastatic Tumor
9%
Advanced or Metastatic
9%
Atomoxetine
9%
Merkel Cell Carcinoma
9%
Investigational New Drug
9%
Relatlimab
9%
Median Overall Survival
9%
Standard Risk
9%
Immunohistochemistry
9%
Pretransplant
8%
Del17p
8%
Disease Progression
8%
Long-term Survival
7%
Medicine and Dentistry
Multiple Myeloma
68%
Melanoma
60%
Overall Survival
48%
Neoplasm
35%
Autologous Hematopoietic Stem Cell Transplantation
34%
Progression Free Survival
33%
Transplantation
26%
Malignant Neoplasm
26%
Hematopoietic Cell
23%
Cell Transplantation
22%
Diseases
20%
Melanoma Skin Cancer
18%
Lenalidomide
17%
Nivolumab
14%
Autologous Stem Cell Transplantation
14%
Immune Checkpoint Blockade
13%
Hazard Ratio
12%
Stem Cell Transplant
12%
Selinexor
12%
Acral Lentiginous Melanoma
12%
Solid Malignant Neoplasm
12%
Hematopoietic Stem Cell Transplantation
12%
Sentinel Lymph Node
11%
Adverse Event
11%
Lymphoma
10%
Prognostic Factor
10%
Allogeneic Stem Cell Transplantation
10%
Recurrence Free Survival
9%
Immunohistochemistry
9%
Atomoxetine
9%
Merkel Cell Carcinoma
9%
Relatlimab
9%
Autotransplantation
9%
Ipilimumab
8%
Lymphovascular Invasion
8%
Disease Exacerbation
8%
Metastatic Carcinoma
8%
Nevus
7%
Cancer
7%
Minimal Residual Disease
7%
Survival Rate
7%
Graft Versus Host Reaction
7%
Immunoglobulin Producing Cell
7%
Clinical Trial
7%
Myeloma
7%
Acute Myeloid Leukemia
7%
Myelodysplastic Syndrome
6%
Metastatic Melanoma
6%
Allograft
6%
Acute Lymphoblastic Leukemia
6%
Pharmacology, Toxicology and Pharmaceutical Science
Multiple Myeloma
47%
Overall Survival
44%
Progression Free Survival
33%
Selinexor
28%
Solid Malignant Neoplasm
25%
Neoplasm
23%
Adverse Event
21%
Diseases
20%
Melanoma
19%
Attention Deficit Disorder
18%
Atomoxetine
18%
Placebo
15%
Lenalidomide
14%
Chemotherapy
11%
Myelodysplastic Syndrome
10%
Busulfan
10%
Carboplatin
10%
Cutaneous Melanoma
9%
Paclitaxel
9%
Graft Versus Host Reaction
7%
Malignant Neoplasm
7%
Lymphoma
7%
Clinical Trial
7%
Ipilimumab
7%
Remission
7%
Tolerability
6%
Fludarabine
6%
Rapamycin
6%
Topotecan
6%
Oppositional Defiant Disorder
6%
Non Insulin Dependent Diabetes Mellitus
6%
Olanzapine
6%
Bone Marrow Depression
6%
Brain Metastasis
6%
Pembrolizumab
6%
Acute Myeloid Leukemia
6%
Exendin 4
6%
Nivolumab
5%
Recurrence Free Survival
5%
Bortezomib
5%
Minimal Residual Disease
5%
Comorbidity
5%
Survival Rate
5%